C
Clene Nanomedicine
Biotech & Life Sciences · Salt Lake City, United States · Founded 2012 · IPO 2020
Biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases MoreLess
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing innovative nanotherapeutics to address cellular energy impairments common in neurodegenerative diseases. The company operates in the biopharmaceutical market, primarily serving patients with conditions such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Clene's business model revolves around the development and commercialization of its proprietary nanocrystal-based therapies, with its lead drug candidate, CNM-Au8, currently in clinical trials. The company generates revenue through equity and debt financings, out-licensing of commercial-stage assets, and potential future sales of its therapeutic products. Clene aims to revolutionize the treatment landscape for neurodegenerative diseases by restoring and protecting neuronal health and function.
Keywords: nanotherapeutics, neurodegenerative diseases, cellular energy, biopharmaceutical, ALS, MS, clinical trials, CNM-Au8, nanocrystals, therapeutic development.
Company overview
Clene Nanomedicine company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Salt Lake City, United States
- Employees
- 71
- Open positions
- None listed
- Dealroom signal
- 45.0
Valuation & funding
Clene Nanomedicine funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $7M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jan 2026 | $28M | — | Vivo Capital · Boxer Capital · Coastlands Capital | ↗ |
| POST IPO EQUITYOther financing | Sep 2025 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2024 | $7.3M | — | Undisclosed | ↗ |
| GRANTOther financing | Oct 2023 | $45M | — | National Institutes of Health | ↗ |
| POST IPO DEBTDebt | Dec 2022 | State of Maryland | ↗ | ||
| GRANTOther financing | Dec 2021 | Undisclosed | — | ||
| IPOOther financing | Dec 2020 | Undisclosed | — | ||
| SERIES DOther financing | Aug 2020 | SymBiosis | — | ||
| DEBTDebt | Feb 2020 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $207K | +3.7% | −$21M | -10178.9% |
| 2025 | $200K | -41.5% | −$21M | -10555.5% |
| 2024 | $342K | -47.7% | −$32M | -9497.4% |
| 2023 | $654K | +38.3% | −$52M | -7958.4% |
| 2022 | $473K | -34.6% | −$45M | -9529.2% |
| 2021 | $723K | +251% | −$48M | -6704.1% |
| 2020 | $206K | — | −$16M | -7770.4% |
Growth signals
Clene Nanomedicine website traffic
Latest recorded traffic for Clene Nanomedicine is 6.5K monthly website visits, up 91.2% over the last three months. Clene Nanomedicine's team grew 4.4% over the past year.
Comparisons
Clene Nanomedicine compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Clene Nanomedicine's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Clene Nanomedicine has talent and traffic
team presence
In the news
Latest news about Clene Nanomedicine
Recent press, funding announcements, and product moves mentioning Clene Nanomedicine — open to read from the original sources.
Market sentiment
What the market is saying about Clene Nanomedicine
An AI-synthesized read of the highest-engagement posts about Clene Nanomedicine on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clene Nanomedicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.